Treatment of community-associated methicillin-resistant Staphylococcus aureus

Current Infectious Disease Reports

Volumn 9, Issue 5, 2007, Pages 398-407

  Popovich, Kyle J ^a   Hota, Bala ^a   Weinstein, Robert A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACITRACIN; CEFTOBIPROLE; CHLORHEXIDINE; CHLORHEXIDINE GLUCONATE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; FUSIDIC ACID; GATIFLOXACIN; GENTAMICIN; LINEZOLID; METICILLIN; MINOCYCLINE; MOXIFLOXACIN; ORITAVANCIN; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETAPAMULIN; RIFAMPICIN; STAPHYLOCOCCUS VACCINE; SULFADIAZINE SILVER; TEA TREE OIL; TELAVANCIN; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BONE MARROW SUPPRESSION; CLINICAL PRACTICE; COMMUNICABLE DISEASE; DISEASE SEVERITY; DISINFECTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG HALF LIFE; GYNECOMASTIA; HAND WASHING; HOSPITALIZATION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MEDICAL DECISION MAKING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MYOPATHY; NECROTIZING FASCIITIS; OUTPATIENT CARE; PERSONAL HYGIENE; REVIEW; RISK FACTOR; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; TREATMENT FAILURE; WOUND CARE;

EID: 34548730346     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-007-0062-8     Document Type: Review

References (83)

1. Fridkin SK, Hageman JC, Morrison M, et al.: Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005, 352:1436-1444.
2. Miller LG, Perdreau-Remington F, Bayer AS, et al.: Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis 2007, 44:471-482.
3. Vandenesch F, Naimi T, Enright MC, et al.: Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003, 9:978-984.
4. Witte W, Cuny C, Strommenger B, et al.: Emergence of a new community acquired MRSA strain in Germany. Euro Surveill 2004, 9:16-18.
5. Larsen A, Stegger M, Goering R, et al.: Emergence and dissemination of the methicillin resistant Staphylococcus aureus USA300 clone in Denmark (2000-2005). Euro Surveill 2007, 12, Epub ahead of print.
6. Kluytmans J, van Belkum A, Verbrugh H: Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997, 10:505-520.
7. von Eiff C, Becker K, Machka K, et al.: Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 2001, 344:11-16.
8. Kuehnert MJ, Kruszon-Moran D, Hill HA, et al.: Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis 2006, 193:172-179.
9. Harbarth S, Liassine N, Dharan S, et al.: Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2000, 31:1380-1385.
10. Harbarth S, Dharan S, Liassine N, et al.: Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999, 43:1412-1416.
11. Boyce JM, Havill NL, Maria B: Frequency and possible infection control implications of gastrointestinal colonization with methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005, 43:5992-5995.
12. Creech CB 2nd, Kernodle DS, Alsentzer A, et al.: Increasing rates of nasal carriage of methicillin-resistant Staphylococcus aureus in healthy children. Pediatr Infect Dis J 2005, 24:617-621.
13. Lee JH: Methicillin (Oxacillin)-resistant Staphylococcus aureus strains isolated from major food animals and their potential transmission to humans. Appl Environ Microbiol 2003, 69:6489-6494.
14. Weese JS, Dick H, Willey BM, et al.: Suspected transmission of methicillin-resistant Staphylococcus aureus between domestic pets and humans in veterinary clinics and in the household. Vet Microbiol 2006, 115:148-155.
15. Ellis MW, Hospenthal DR, Dooley DP, et al.: Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis 2004, 39:971-979.
16. Popovich KJ, Weinstein RA, Rice T, et al.: Are community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) strains replacing traditional nosocomial MRSA? Presented at the 17th Society for Healthcare Epidemiology of America Meeting. Baltimore; April 14-17, 2007.
17. Miller LG, Perdreau-Remington F, Rieg G, et al.: Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005, 352:1445-1453.
18. Lee MC, Rios AM, Aten MF, et al.: Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004, 23:123-127.
19. Ruhe JJ, Smith N, Bradsher RW, Menon A: Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis 2007, 44:777-784.
20. Gorwitz RJ: The role of ancillary antimicrobial therapy for treatment of uncomplicated skin infections in the era of community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007, 44:785-787.
21. Gorwitz RJ, Jernigan DB, Powers JH; et al.: Strategies for clinical management of MRSA in the community: Summary of an experts' meeting convened by the Centers for Disease Control and Prevention. Available at http://www.cdc.gov/ncidod/dhqp/pdf/ar/CAMRSA_ExpMtgStrategies.pdf. Accessed June 21, 2007.
22. Stevens DL, Bisno AL, Chambers HF, et al.: Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005, 41:1373-1406.
23. Barnes EV 2nd, Dooley DP, Hepburn MJ, Baum SE: Outcomes of community-acquired, methicillin-resistant Staphylococcus aureus, soft tissue infections treated with antibiotics other than vancomycin. Mil Med 2006, 171:504-507.
24. Micek ST, Dunne M, Kollef MH: Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005, 128:2732-2738.
25. Huang H, Flynn NM, King JH, et al.: Comparisons of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and hospital-associated MSRA infections in Sacramento, California. J Clin Microbiol 2006, 44:2423-2427.
26. Patel M, Waites KB, Moser SA, et al.: Prevalence of inducible clindamycin resistance among community- and hospital-associated Staphylococcus aureus isolates. J Clin Microbiol 2006, 44:2481-2484.
27. Tamayo J, Perez-Trallero E, Gomez-Garces JL, Alos JI: Resistance to macrolides, clindamycin and telithromycin in Streptococcus pyogenes isolated in Spain during 2004. J Antimicrob Chemother 2005, 56:780-782.
28. Ruhe JJ, Monson T, Bradsher RW, Menon A: Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005, 40:1429-1434.
29. Weese JS, Archambault M, Willey BM, et al.: Methicillin-resistant Staphylococcus aureus in horses and horse personnel, 2000-2002. Emerg Infect Dis 2005, 11:430-435.
30. York MK, Gibbs L, Perdreau-Remington F, Brooks GF: Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of northern California. J Clin Microbiol 1999, 37:1727-1731.
31. Nielsen HU, Hammerum AM, Ekelund K, et al.: Tetracycline and macrolide co-resistance in Streptococcus pyogenes: co-selection as a reason for increase in macrolide-resistant S. pyogenes? Microb Drug Resist 2004, 10:231-238.
32. Fowler VG Jr, Kong LK, Corey GR, et al.: Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 1999, 179:1157-1161.
33. Stevens DL: The role of vancomycin in the treatment paradigm. Clin Infect Dis 2006, 42(Suppl 1):S51-57.
34. Wang G, Hindler JF, Ward KW, Bruckner DA: Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006, 44:3883-3886.
35. Tenover FC, Moellering RC Jr: The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007, 44:1208-1215.
36. Sakoulas G, Moise-Broder PA, Schentag J, et al.: Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004, 42:2398-2402.
37. Graber CJ, Wong MK, Carleton HA, et al.: Intermediate vancomycin susceptibility in a community-associated MRSA clone. Emerg Infect Dis 2007, 13:491-493.
38. Kleinschmidt SL, Munckhof WJ, Nimmo GR: In vitro exposure of community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains to vancomycin: does vancomycin resistance occur? Int J Antimicrob Agents 2006, 27:168-1.70.
39. American Thoracic Society, Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
40. Hidayat LK, Hsu DI, Quist R, et al.: High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006, 166:2138-2144.
41. Lipsky BA, Itani K, Norden C: Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004, 38:17-24.
42. Meka VG, Gold HS: Antimicrobial resistance to linezolid. Clin Infect Dis 2004, 39:1010-1015.
43. Fowler VG Jr, Boucher HW, Corey GR, et al.: Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355:653-665.
44. Skiest DJ: Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006, 44:655-656.
45. Papadopoulos S, Ball AM, Liewer SE, et al.: Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis 2006, 42:e108-110.
46. Blumberg HM, Rimland D, Carroll DJ, et al.: Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis 1991, 163:1279-1285.
47. Strausbaugh LJ, Jacobson C, Sewell DL, et al.: Antimicrobial therapy for methicillin-resistant Staphylococcus aureus colonization in residents and staff of a Veterans Affairs nursing home care unit. Infect Control Hosp Epidemiol 1992, 13:151-159.
48. Ellis MW, Lewis JS 2nd: Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr Opin Infect Dis 2005, 18:496-501.
49. Postier RG, Green SL, Klein SR, et al.: Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004, 26:704-714.
50. Streit JM, Fritsche TR, Sader HS, Jones RN: Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 2004, 48:137-143.
51. Allen NE, Nicas TI: Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev 2003, 26:511-532.
52. Stryjewski ME, O'Riordan WD, Lau WK, et al.: Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005, 40:1601-1607.
53. Appelbaum PC: MRSA - the tip of the iceberg. Clin Microbiol Infect 2006, 12(Suppl 2):3-10.
54. Weston VC, Boswell TC, Finch RG, Perkins W: Fusidic acid cream for impetigo. Emergence of resistance to fusidic acid limits its use. BMJ 2002, 324:1394.
55. Gosbell IB: Methicillin-resistant Staphylococcus aureus: impact on dermatology practice. Am J Clin Dermatol 2004, 5:239-259.
56. Halcon L, Milkus K: Staphylococcus aureus and wounds: a review of tea tree oil as a promising antimicrobial. Am J Infect Control 2004, 32:402-408.
57. Dryden MS, Dailly S, Crouch M: A randomized, controlled trial of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonization. J Hosp Infect 2004, 56:283-286.
58. Henley DV, Lipson N, Korach KS, Bloch CA: Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med 2007, 356:479-485.
59. McMahon MA, Blair IS, Moore JE, McDowell DA: Habituation to sub-lethal concentrations of tea tree oil (Melaleuca alternifolia) is associated with reduced susceptibility to antibiotics in human pathogens. J Antimicrob Chemother 2007, 59:125-127.
60. Gentry DR, Rittenhouse SF, McCloskey L, Holmes DJ: Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin. Antimicrob Agents Chemother 2007, 51:2048-2052.
61. Rittenhouse S, Biswas S, Broskey J, et al.: Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob Agents Chemother 2006, 50:3882-3885.
62. Wootton SH, Arnold K, Hill HA, et al.: Intervention to reduce the incidence of methicillin-resistant Staphylococcus aureus skin infections in a correctional facility in Georgia. Infect Control Hosp Epiderniol 2004, 25:402-407.
63. Klempner MS, Styrt B: Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. JAMA 1988, 260:2682-2685.
64. Martin MA: Methicillin-resistant Staphylococcus aureus: the persistent resistant nosocomial pathogen. Curr Clin Top Infect Dis 1994, 14:170-191.
65. Shinefield H, Black S, Fattom A, et al.: Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002, 346:491-496.
66. Eveillard M, de Lassence A, Lancien E, et al.: Evaluation of a strategy of screening multiple anatomical sites for methicillin-resistant Staphylococcus aureus at admission to a teaching hospital. Infect Control Hosp Epidemiol 2006, 27:181-184.
67. Rihn JA, Posfay-Barbe K, Harner CD, et al.: Community-acquired methicillin-resistant Staphylococcus aureus outbreak in a local high school football team unsuccessful interventions. Pediatr Infect Dis J 2005, 24:841-843.
68. Raz R, Miron D, Colodner R, et al.: A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Arch Intern Med 1996, 156:1109-1112.
69. Perl TM, Cullen JJ, Wenzel RP, et al.: Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 2002, 346:1871-1877.
70. Doebbeling BN, Reagan DR, Pfaller MA, et al.: Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage. Arch Intern Med 1994, 154:1505-1508.
71. Diep BA, Gill SR, Chang RF, et al.: Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 2006, 367:731-739.
72. Coia JE, Duckworth GJ, Edwards DI, et al.: Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect 2006, 63(Suppl 1):S1-44.
73. Simor AE, Phillips E, McGeer A, et al.: Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 2007, 44:178-185.
74. Sandri AM, Dalarosa MG, Ruschel de Alcantara L, et al.: Reduction in incidence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in an intensive care unit: role of treatment with mupirocin ointment and chlorhexidine baths for nasal carriers of MRSA. Infect Control Hosp Epidemiol 2006, 27:185-187.
75. Cohen PR, Grossman ME: Management of cutaneous lesions associated with an emerging epidemic: community-acquired methicillin-resistant Staphylococcus aureus skin infections. J Am Acad Dermatol 2004, 51:132-135.
76. Guilhermetti M, Hernandes SE, Fukushigue Y, et al.: Effectiveness of hand-cleansing agents for removing methicillin-resistant Staphylococcus aureus from contaminated hands. Infect Control Hosp Epidemiol 2001, 22:105-108.
77. Yu VL, Goetz A, Wagener M, et al.: Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med 1986, 315:91-96.
78. Caelli M, Porteous J, Carson CF, et al.: Tea tree oil as an alternative topical decolonization agent for methicillin-resistant Staphylococcus aureus. J Hosp Infect 2000, 46:236-237.
79. Wiese-Posselt M, Heuck D, Draeger A, et al.: Successful termination of a furunculosis outbreak due to lukS-lukF-positive, methicillin-susceptible Staphylococcus aureus in a German village by stringent decolonization, 2002-2005. Clin Infect Dis 2007, 44:e88-95.
80. Dellit T, Duchin J, Hofmann J, Olson EG: Interim guidelines for evaluation and management of community-associated methicillin-resistant staphylococcus aureus skin and soft tissue infections in outpatient setting. Available at http://www.doh.wa.gov/Topics/ AntibioticslMRSAInterim.htm. Accessed June 21, 2007.
81. Muto CA, Jernigan JA, Ostrowsky BE, et al.: SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003, 24:362-386.
82. Garner JS: Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996, 17:53-80.
83. Boyce JM, Pittet D: Guideline for Hand Hygiene in HealthCare Settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep 2002, 51(RR-16):1-45, quiz CE1-4.